Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 3/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 11/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 4/20 | 0.35 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12367267 | 0.82 | SYK (0.43) | RAB9AHSP90AA1SYKPDPK1SRC | |
| SCHEMBL2185604 | 0.75 | MCL1 (0.35) | RAB9AHSP90AA1SYKSRCZAP70 | |
| SCHEMBL2184656 | 0.74 | RAB9A (0.49) | RAB9AHSP90AA1SYKPDPK1SRC | |
| SCHEMBL5106809 | 0.73 | MEN1 (0.48) | RAB9APDE4APDE4CPDE4DCYP1A2 | |
| SCHEMBL2185193 | 0.73 | PDE4A (0.37) | PDE4APDE4CPDE4D | |
| SCHEMBL4902877 | 0.73 | RAB9A (0.61) | RAB9AHSP90AA1SYKPDPK1SRC | |
| SCHEMBL1710223 | 0.72 | METAP2 (0.39) | RAB9APDE4APDE4CPDE4DPDPK1 | |
| SCHEMBL27911185 | 0.71 | RAB9A (0.43) | RAB9AHSP90AA1SYKPDPK1SRC | |
| SCHEMBL25406591 | 0.69 | PDE4A (0.40) | RAB9APDE4APDE4CPDE4DSYK | |
| SCHEMBL1018225 | 0.69 | PDE4A (0.45) | PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2342190-A1 | BICYCLIC KINASE INHIBITORS | Novartis AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | RAB9A 3490/4885HSP90AA1 2771/4885PDE4A 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.